cagrisema semaglutide cagrilintide combination trial 5mg + 5mg Cagrilintide–semaglutide (CagriSema) versus semaglutide or

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as key therapies for the treatment of obesity and type 2 diabetes, with several agents demonstrating cardiovascular benefits 7,8,9,10,11,12

It is worth noting that both metformin and Rybelsus can potentially yield similar side effects, such as nausea, vomiting, diarrhea, belly pain, constipation, upset stomach, and gas

On the other hand, side effects related to stopping, such as increased hunger, food cravings and the return of food noise, may begin before the medication has fully cleared and can persist unless other weight-management strategies are in place

Early signs include reduced appetite, smaller portion sizes, decreased food cravings, less interest in high-calorie snacks, and what many describe as quieter "food noise." These appetite and behavioral changes typically precede visible weight loss by several weeks

Quick Answer: Weakness on semaglutide typically results from reduced caloric intake due to appetite suppression, gastrointestinal side effects causing dehydration and electrolyte imbalances, and rapid weight loss rather than direct medication toxicity